Sinsin Pharmaceutical Co., Ltd

KOSDAQ:A002800 Stock Report

Market Cap: ₩80.7b

Sinsin Pharmaceutical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Ki Lee Byoung

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.3%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

What Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) 40% Share Price Gain Is Not Telling You

Jul 30
What Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) 40% Share Price Gain Is Not Telling You

Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues

Mar 20
Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues

What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?

Mar 06
What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?

Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?

Feb 08
Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?

If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today

Jan 18
If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today

We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability

Dec 25
We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability

What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?

Nov 29
What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?

CEO

Ki Lee Byoung

no data

Tenure

Ki Lee Byoung is President & CEO of Sinsin Pharmaceutical Co., Ltd.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 19:16
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinsin Pharmaceutical Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution